FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
 & Lead Plaintiff Deadline: June 19, 2017 - EconoTimes)
NEW YORK, May 10, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NYSE:TXMD) securities and certain of its officers, on behalf of a class who purchased TherapeuticsMD securities between July 7, 2016 and April 9, 2017, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/txmd.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that the TherapeuticsMD’s New Drug Application (“NDA”) submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the Food & Drug Administration’s potential approval of the NDA. On April 10, 2017, the Company announced that the U.S. Food & Drug Administration had found deficiencies in its NDA for TX-004HR.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/txmd or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
